Rabies is almost 100% fatal once symptoms appear. But it's also 100% preventable with prompt vaccination. The human rabies vaccine market report by MRFR shows that post‑exposure prophylaxis (PEP) accounts for 67% of vaccine use, because every year, millions of people are bitten by suspect animals. The market is $624 million and growing at 7% CAGR, driven by rising dog populations and better surveillance in Asia and Africa.

What does PEP involve? Ideally, a dose of rabies immunoglobulin (HRIG) plus four vaccine doses over two weeks. But HRIG is expensive and often in short supply. That's why the human rabies vaccine market analysis highlights that equine rabies immunoglobulin (ERIG) is the fastest‑growing immunoglobulin segment — it's cheaper, though slightly higher risk of allergic reactions.

Intradermal vaccination (ID) is another game‑changer. It uses 80% less vaccine than intramuscular (IM) shots, making mass campaigns affordable. The WHO now recommends ID for PEP in resource‑limited settings.

If you're traveling to a rabies‑endemic area (most of Asia, Africa, and parts of Latin America), consider pre‑exposure vaccination (PrEP). It simplifies PEP if you're bitten — no HRIG needed, just two booster shots. It's not cheap, but neither is your life.